Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

June 08, 2007 18:28 ET

Urodynamix Announces Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 8, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) reported today that it has issued 600,000 incentive stock options to four directors of the company. The stock options are being offered in conformance with TSX Venture Exchange regulations as part of director compensation and have a term of five years and an exercise price of $0.24 per share.

Urodynamix currently has outstanding 67,726,087 common shares, 14,414,305 warrants and 6,909,000 incentive stock options. The company's Stock Option Plan allows the Board to issue the equivalent of up to 10% of the issued and outstanding share capital of the company on a rolling basis and was approved at the company's last Annual General Meeting held on June 4, 2007.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information